Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 238

1.

Nanobody-Based High-Performance Immunosorbent for Selective Beta 2-microglobulin Purification from Blood.

Huang C, Ren J, Ji F, Muyldermans S, Jia L.

Acta Biomater. 2020 Feb 21. pii: S1742-7061(20)30116-1. doi: 10.1016/j.actbio.2020.02.028. [Epub ahead of print]

PMID:
32092428
2.

Reshaping nanobodies for affinity purification on protein a.

Crauwels M, Van Vaerenbergh N, Kulaya NB, Vincke C, D'Huyvetter M, Devoogdt N, Muyldermans S, Xavier C.

N Biotechnol. 2020 Jan 27;57:20-28. doi: 10.1016/j.nbt.2020.01.005. [Epub ahead of print]

3.

Paradigm shift in the diagnosis of peste des petits ruminants: scoping review.

Kinimi E, Odongo S, Muyldermans S, Kock R, Misinzo G.

Acta Vet Scand. 2020 Jan 29;62(1):7. doi: 10.1186/s13028-020-0505-x. Review.

4.

Identification of Nanobodies against the Acute Myeloid Leukemia Marker CD33.

Romão E, Krasniqi A, Maes L, Vandenbrande C, Sterckx YG, Stijlemans B, Vincke C, Devoogdt N, Muyldermans S.

Int J Mol Sci. 2020 Jan 2;21(1). pii: E310. doi: 10.3390/ijms21010310.

5.

Liposomal delivery of vascular endothelial growth factor/receptors and their inhibitors.

Khodabakhsh F, Muyldermans S, Behdani M, Kazemi-Lomedasht F.

J Drug Target. 2019 Dec 10:1-7. doi: 10.1080/1061186X.2019.1693578. [Epub ahead of print]

PMID:
31822133
6.

The Therapeutic Potential of Nanobodies.

Jovčevska I, Muyldermans S.

BioDrugs. 2020 Feb;34(1):11-26. doi: 10.1007/s40259-019-00392-z. Review.

7.

Development of anti-matrix metalloproteinase-2 (MMP-2) nanobodies as potential therapeutic and diagnostic tools.

Marturano A, Hendrickx MLV, Falcinelli E, Sebastiano M, Guglielmini G, Hassanzadeh-Ghassabeh G, Muyldermans S, Declerck PJ, Gresele P.

Nanomedicine. 2019 Oct 24;24:102103. doi: 10.1016/j.nano.2019.102103. [Epub ahead of print]

PMID:
31669421
8.

Increased Expression of Adherens Junction Components in Mouse Liver following Bile Duct Ligation.

Van Campenhout R, Crespo Yanguas S, Cooreman A, Gijbels E, Leroy K, Vilas-Boas V, Devoogdt N, Muyldermans S, Cogliati B, Vinken M.

Biomolecules. 2019 Oct 22;9(10). pii: E636. doi: 10.3390/biom9100636.

9.

Identification of New DR5 Agonistic Nanobodies and Generation of Multivalent Nanobody Constructs for Cancer Treatment.

Sadeghnezhad G, Romão E, Bernedo-Navarro R, Massa S, Khajeh K, Muyldermans S, Hassania S.

Int J Mol Sci. 2019 Sep 27;20(19). pii: E4818. doi: 10.3390/ijms20194818.

10.

Development of a mono-specific anti-VEGF bivalent nanobody with extended plasma half-life for treatment of pathologic neovascularization.

Sadeghi A, Behdani M, Muyldermans S, Habibi-Anbouhi M, Kazemi-Lomedasht F.

Drug Test Anal. 2020 Jan;12(1):92-100. doi: 10.1002/dta.2693. Epub 2019 Sep 12.

PMID:
31476257
11.

Fast One-Step Ultrasensitive Detection of Toxocara canis Antigens by a Nanobody-Based Electrochemical Magnetosensor.

Morales-Yánez F, Trashin S, Hermy M, Sariego I, Polman K, Muyldermans S, De Wael K.

Anal Chem. 2019 Sep 17;91(18):11582-11588. doi: 10.1021/acs.analchem.9b01687. Epub 2019 Aug 30.

PMID:
31429269
12.

Soluble aggregates present in cerebrospinal fluid change in size and mechanism of toxicity during Alzheimer's disease progression.

De S, Whiten DR, Ruggeri FS, Hughes C, Rodrigues M, Sideris DI, Taylor CG, Aprile FA, Muyldermans S, Knowles TPJ, Vendruscolo M, Bryant C, Blennow K, Skoog I, Kern S, Zetterberg H, Klenerman D.

Acta Neuropathol Commun. 2019 Jul 26;7(1):120. doi: 10.1186/s40478-019-0777-4.

13.

Site-Selective Functionalization of Nanobodies Using Intein-Mediated Protein Ligation for Innovative Bioconjugation.

Graulus GJ, Ta DT, Tran H, Hansen R, Billen B, Royackers E, Noben JP, Devoogdt N, Muyldermans S, Guedens W, Adriaensens P.

Methods Mol Biol. 2019;2033:117-130. doi: 10.1007/978-1-4939-9654-4_9.

PMID:
31332751
14.

NIRF-Molecular Imaging with Synovial Macrophages-Targeting Vsig4 Nanobody for Disease Monitoring in a Mouse Model of Arthritis.

Zheng F, Luo S, Ouyang Z, Zhou J, Mo H, Schoonooghe S, Muyldermans S, De Baetselier P, Raes G, Wen Y.

Int J Mol Sci. 2019 Jul 8;20(13). pii: E3347. doi: 10.3390/ijms20133347.

15.

An innovative approach in the detection of Toxocara canis excretory/secretory antigens using specific nanobodies.

Morales-Yanez FJ, Sariego I, Vincke C, Hassanzadeh-Ghassabeh G, Polman K, Muyldermans S.

Int J Parasitol. 2019 Jul;49(8):635-645. doi: 10.1016/j.ijpara.2019.03.004. Epub 2019 May 29.

16.

Llama peripheral B-cell populations producing conventional and heavy chain-only IgG subtypes are phenotypically indistinguishable but immunogenetically distinct.

Henry KA, van Faassen H, Harcus D, Marcil A, Hill JJ, Muyldermans S, MacKenzie CR.

Immunogenetics. 2019 Apr;71(4):307-320. doi: 10.1007/s00251-018-01102-9. Epub 2019 Jan 18.

PMID:
30656359
17.

Understanding the Significance and Implications of Antibody Numbering and Antigen-Binding Surface/Residue Definition.

Dondelinger M, Filée P, Sauvage E, Quinting B, Muyldermans S, Galleni M, Vandevenne MS.

Front Immunol. 2018 Oct 16;9:2278. doi: 10.3389/fimmu.2018.02278. eCollection 2018. Review.

18.

Guided Evolution of Recombinant Bombyx mori Acetylcholinesterase II by Homology Modeling to Change Pesticide Sensitivity.

Cai J, Wang B, Li J, Chen Z, Rao M, Muyldermans S, Hua X, Xie X, Wang H, Yang J, Xu Z, Shen Y, Sun Y.

Int J Mol Sci. 2018 Oct 27;19(11). pii: E3366. doi: 10.3390/ijms19113366.

19.

The Development and Validation of a Novel Nanobody-Based Competitive ELISA for the Detection of Foot and Mouth Disease 3ABC Antibodies in Cattle.

Gelkop S, Sobarzo A, Brangel P, Vincke C, Romão E, Fedida-Metula S, Strom N, Ataliba I, Mwiine FN, Ochwo S, Velazquez-Salinas L, McKendry RA, Muyldermans S, Lutwama JJ, Rieder E, Yavelsky V, Lobel L.

Front Vet Sci. 2018 Oct 12;5:250. doi: 10.3389/fvets.2018.00250. eCollection 2018.

20.

Nanobodies as novel therapeutic agents in envenomation.

Alirahimi E, Kazemi-Lomedasht F, Shahbazzadeh D, Habibi-Anbouhi M, Hosseininejad Chafi M, Sotoudeh N, Ghaderi H, Muyldermans S, Behdani M.

Biochim Biophys Acta Gen Subj. 2018 Dec;1862(12):2955-2965. doi: 10.1016/j.bbagen.2018.08.019. Epub 2018 Aug 30. Review.

PMID:
30309831
21.

Site-Specific Radioactive Labeling of Nanobodies.

Crauwels M, Massa S, Martin C, Betti C, Ballet S, Devoogdt N, Xavier C, Muyldermans S.

Methods Mol Biol. 2018;1827:505-540. doi: 10.1007/978-1-4939-8648-4_26.

PMID:
30196514
22.

Blocking EGFR Activation with Anti-EGF Nanobodies via Two Distinct Molecular Recognition Mechanisms.

Guardiola S, Varese M, Sánchez-Navarro M, Vincke C, Teixidó M, García J, Muyldermans S, Giralt E.

Angew Chem Int Ed Engl. 2018 Oct 15;57(42):13843-13847. doi: 10.1002/anie.201807736. Epub 2018 Sep 21.

PMID:
30152597
23.

Development of a Nanobody-based lateral flow assay to detect active Trypanosoma congolense infections.

Pinto Torres JE, Goossens J, Ding J, Li Z, Lu S, Vertommen D, Naniima P, Chen R, Muyldermans S, Sterckx YG, Magez S.

Sci Rep. 2018 Jun 13;8(1):9019. doi: 10.1038/s41598-018-26732-7.

24.

The structural basis of nanobody unfolding reversibility and thermoresistance.

Kunz P, Zinner K, Mücke N, Bartoschik T, Muyldermans S, Hoheisel JD.

Sci Rep. 2018 May 21;8(1):7934. doi: 10.1038/s41598-018-26338-z.

25.

Glioblastoma-specific anti-TUFM nanobody for in-vitro immunoimaging and cancer stem cell targeting.

Samec N, Jovcevska I, Stojan J, Zottel A, Liovic M, Myers MP, Muyldermans S, Šribar J, Križaj I, Komel R.

Oncotarget. 2018 Apr 3;9(25):17282-17299. doi: 10.18632/oncotarget.24629. eCollection 2018 Apr 3.

26.

Combinatorial Design of a Nanobody that Specifically Targets Structured RNAs.

Cawez F, Duray E, Hu Y, Vandenameele J, Romão E, Vincke C, Dumoulin M, Galleni M, Muyldermans S, Vandevenne M.

J Mol Biol. 2018 May 25;430(11):1652-1670. doi: 10.1016/j.jmb.2018.03.032. Epub 2018 Apr 11.

27.

Pharmacokinetics of radiolabeled dimeric sdAbs constructs targeting human CD20.

Krasniqi A, Bialkowska M, Xavier C, Van der Jeught K, Muyldermans S, Devoogdt N, D'Huyvetter M.

N Biotechnol. 2018 Oct 25;45:69-79. doi: 10.1016/j.nbt.2018.03.004. Epub 2018 Mar 21.

PMID:
29574274
28.

Design of a humanized anti vascular endothelial growth factor nanobody and evaluation of its in vitro function.

Kazemi-Lomedasht F, Muyldermans S, Habibi-Anbouhi M, Behdani M.

Iran J Basic Med Sci. 2018 Mar;21(3):260-266. doi: 10.22038/ijbms.2018.24898.6183.

29.

Structural Basis for the Specific Neutralization of Stx2a with a Camelid Single Domain Antibody Fragment.

Bernedo-Navarro RA, Romão E, Yano T, Pinto J, De Greve H, Sterckx YG, Muyldermans S.

Toxins (Basel). 2018 Mar 1;10(3). pii: E108. doi: 10.3390/toxins10030108.

30.

Novel half-life extended anti-MIF nanobodies protect against endotoxic shock.

Sparkes A, De Baetselier P, Brys L, Cabrito I, Sterckx YG, Schoonooghe S, Muyldermans S, Raes G, Bucala R, Vanlandschoot P, Van Ginderachter JA, Stijlemans B.

FASEB J. 2018 Jun;32(6):3411-3422. doi: 10.1096/fj.201701189R. Epub 2018 Jan 25.

31.

Nanobodies As Novel Agents for Targeting Angiogenesis in Solid Cancers.

Arezumand R, Alibakhshi A, Ranjbari J, Ramazani A, Muyldermans S.

Front Immunol. 2017 Dec 8;8:1746. doi: 10.3389/fimmu.2017.01746. eCollection 2017. Review.

32.

Inhibiting the Ca2+ Influx Induced by Human CSF.

Drews A, De S, Flagmeier P, Wirthensohn DC, Chen WH, Whiten DR, Rodrigues M, Vincke C, Muyldermans S, Paterson RW, Slattery CF, Fox NC, Schott JM, Zetterberg H, Dobson CM, Gandhi S, Klenerman D.

Cell Rep. 2017 Dec 12;21(11):3310-3316. doi: 10.1016/j.celrep.2017.11.057.

33.

Nanobody-Based Delivery Systems for Diagnosis and Targeted Tumor Therapy.

Hu Y, Liu C, Muyldermans S.

Front Immunol. 2017 Nov 2;8:1442. doi: 10.3389/fimmu.2017.01442. eCollection 2017. Review.

34.

A nanobody-based tracer targeting DPP6 for non-invasive imaging of human pancreatic endocrine cells.

Balhuizen A, Massa S, Mathijs I, Turatsinze JV, De Vos J, Demine S, Xavier C, Villate O, Millard I, Egrise D, Capito C, Scharfmann R, In't Veld P, Marchetti P, Muyldermans S, Goldman S, Lahoutte T, Bouwens L, Eizirik DL, Devoogdt N.

Sci Rep. 2017 Nov 9;7(1):15130. doi: 10.1038/s41598-017-15417-2.

35.

Construction of High-Quality Camel Immune Antibody Libraries.

Romão E, Poignavent V, Vincke C, Ritzenthaler C, Muyldermans S, Monsion B.

Methods Mol Biol. 2018;1701:169-187. doi: 10.1007/978-1-4939-7447-4_9.

PMID:
29116505
36.

Theranostic Radiolabeled Anti-CD20 sdAb for Targeted Radionuclide Therapy of Non-Hodgkin Lymphoma.

Krasniqi A, D'Huyvetter M, Xavier C, Van der Jeught K, Muyldermans S, Van Der Heyden J, Lahoutte T, Tavernier J, Devoogdt N.

Mol Cancer Ther. 2017 Dec;16(12):2828-2839. doi: 10.1158/1535-7163.MCT-17-0554. Epub 2017 Oct 20.

37.

Structural basis for the high specificity of a Trypanosoma congolense immunoassay targeting glycosomal aldolase.

Pinto J, Odongo S, Lee F, Gaspariunaite V, Muyldermans S, Magez S, Sterckx YG.

PLoS Negl Trop Dis. 2017 Sep 15;11(9):e0005932. doi: 10.1371/journal.pntd.0005932. eCollection 2017 Sep.

38.

Nanobody-mediated resistance to Grapevine fanleaf virus in plants.

Hemmer C, Djennane S, Ackerer L, Hleibieh K, Marmonier A, Gersch S, Garcia S, Vigne E, Komar V, Perrin M, Gertz C, Belval L, Berthold F, Monsion B, Schmitt-Keichinger C, Lemaire O, Lorber B, Gutiérrez C, Muyldermans S, Demangeat G, Ritzenthaler C.

Plant Biotechnol J. 2018 Feb;16(2):660-671. doi: 10.1111/pbi.12819. Epub 2017 Oct 6.

39.

Generation of Nanobodies against SlyD and development of tools to eliminate this bacterial contaminant from recombinant proteins.

Hu Y, Romão E, Vertommen D, Vincke C, Morales-Yánez F, Gutiérrez C, Liu C, Muyldermans S.

Protein Expr Purif. 2017 Sep;137:64-76. doi: 10.1016/j.pep.2017.06.016. Epub 2017 Jun 28.

PMID:
28668496
40.

Exploiting sequence and stability information for directing nanobody stability engineering.

Kunz P, Flock T, Soler N, Zaiss M, Vincke C, Sterckx Y, Kastelic D, Muyldermans S, Hoheisel JD.

Biochim Biophys Acta Gen Subj. 2017 Sep;1861(9):2196-2205. doi: 10.1016/j.bbagen.2017.06.014. Epub 2017 Jun 20.

41.

Discovery of a novel conformational equilibrium in urokinase-type plasminogen activator.

Kromann-Hansen T, Louise Lange E, Peter Sørensen H, Hassanzadeh-Ghassabeh G, Huang M, Jensen JK, Muyldermans S, Declerck PJ, Komives EA, Andreasen PA.

Sci Rep. 2017 Jun 13;7(1):3385. doi: 10.1038/s41598-017-03457-7.

42.

Inactivation of γ-secretases leads to accumulation of substrates and non-Alzheimer neurodegeneration.

Acx H, Serneels L, Radaelli E, Muyldermans S, Vincke C, Pepermans E, Müller U, Chávez-Gutiérrez L, De Strooper B.

EMBO Mol Med. 2017 Aug;9(8):1088-1099. doi: 10.15252/emmm.201707561.

43.

Differentially expressed proteins in glioblastoma multiforme identified with a nanobody-based anti-proteome approach and confirmed by OncoFinder as possible tumor-class predictive biomarker candidates.

Jovčevska I, Zupanec N, Urlep Ž, Vranič A, Matos B, Stokin CL, Muyldermans S, Myers MP, Buzdin AA, Petrov I, Komel R.

Oncotarget. 2017 Jul 4;8(27):44141-44158. doi: 10.18632/oncotarget.17390.

44.

Ultrasensitive Measurement of Ca2+ Influx into Lipid Vesicles Induced by Protein Aggregates.

Flagmeier P, De S, Wirthensohn DC, Lee SF, Vincke C, Muyldermans S, Knowles TPJ, Gandhi S, Dobson CM, Klenerman D.

Angew Chem Int Ed Engl. 2017 Jun 26;56(27):7750-7754. doi: 10.1002/anie.201700966. Epub 2017 May 5.

45.

Cytoplasmic versus periplasmic expression of site-specifically and bioorthogonally functionalized nanobodies using expressed protein ligation.

Billen B, Vincke C, Hansen R, Devoogdt N, Muyldermans S, Adriaensens P, Guedens W.

Protein Expr Purif. 2017 May;133:25-34. doi: 10.1016/j.pep.2017.02.009. Epub 2017 Feb 24.

PMID:
28238765
46.

Limiting the protein corona: A successful strategy for in vivo active targeting of anti-HER2 nanobody-functionalized nanostars.

D'Hollander A, Jans H, Velde GV, Verstraete C, Massa S, Devoogdt N, Stakenborg T, Muyldermans S, Lagae L, Himmelreich U.

Biomaterials. 2017 Apr;123:15-23. doi: 10.1016/j.biomaterials.2017.01.007. Epub 2017 Jan 6.

PMID:
28152380
47.

Structural evaluation of a nanobody targeting complement receptor Vsig4 and its cross reactivity.

Wen Y, Ouyang Z, Schoonooghe S, Luo S, De Baetselier P, Lu W, Muyldermans S, Raes G, Zheng F.

Immunobiology. 2017 Jun;222(6):807-813. doi: 10.1016/j.imbio.2016.11.008. Epub 2016 Nov 18.

PMID:
27889311
48.

Dromedary immune response and specific Kv2.1 antibody generation using a specific immunization approach.

Hassiki R, Labro AJ, Benlasfar Z, Vincke C, Somia M, El Ayeb M, Muyldermans S, Snyders DJ, Bouhaouala-Zahar B.

Int J Biol Macromol. 2016 Dec;93(Pt A):167-171. doi: 10.1016/j.ijbiomac.2016.06.031. Epub 2016 Jun 16.

PMID:
27320844
49.

Specificity Evaluation and Disease Monitoring in Arthritis Imaging with Complement Receptor of the Ig superfamily targeting Nanobodies.

Zheng F, Perlman H, Matthys P, Wen Y, Lahoutte T, Muyldermans S, Lu S, De Baetselier P, Schoonooghe S, Devoogdt N, Raes G.

Sci Rep. 2016 Oct 25;6:35966. doi: 10.1038/srep35966.

50.

Sortase A-mediated site-specific labeling of camelid single-domain antibody-fragments: a versatile strategy for multiple molecular imaging modalities.

Massa S, Vikani N, Betti C, Ballet S, Vanderhaegen S, Steyaert J, Descamps B, Vanhove C, Bunschoten A, van Leeuwen FW, Hernot S, Caveliers V, Lahoutte T, Muyldermans S, Xavier C, Devoogdt N.

Contrast Media Mol Imaging. 2016 Sep;11(5):328-339. doi: 10.1002/cmmi.1696. Epub 2016 May 5.

PMID:
27147480

Supplemental Content

Loading ...
Support Center